{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-26-041877","form_type":"8-K","ticker":"COCP","cik":"0001412486","company_name":"Cocrystal Pharma, Inc.","filed_at":"2026-09-09T12:00:19+00:00","discovered_at":"2026-09-09T12:05:00.295844+00:00","generated_at":"2026-09-09T12:05:26.558824+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cocrystal Pharma completes dosing in Phase 1b norovirus challenge study for CDI-988","bullets":["Last subject dosed in Phase 1b norovirus challenge study (NCT07198139) evaluating CDI-988 as preventive and treatment.","No serious adverse events reported to date; CDI-988 previously safe at 1200 mg dose in Phase 1.","Preliminary efficacy results expected late 2026 or early 2027.","Study at Emory University enrolled healthy adults 18-49 infected with GII.2 (Snow Mountain Virus) strain.","CDI-988 is first oral antiviral for norovirus, designed to inhibit replication in all known strains."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-26-041877","json":"https://secwatch.observer/filing/0001493152-26-041877.json","markdown":"https://secwatch.observer/filing/0001493152-26-041877.md","text":"https://secwatch.observer/filing/0001493152-26-041877.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/0001493152-26-041877-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1412486/000149315226041877/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-09-09T12:05:26.558824+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}